What is not working for the company?
What is working for the company?
|Name||Dec 22||Sep 22|
|Mutual Funds (Change:0.00)||0%||0%|
|Insurance Companies (Change:0.00)||0%||0%|
|Other DIIs (Change:0.00)||0.06%||0.06%|
|Non Institution (Change:0.00)||26.65%||26.65%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Bombay Oxygen Investments SHARE PRICE [LIVE]
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of Bombay Oxygen Investments Limited ()?
Can I buy Bombay Oxygen Investments Limited () shares?
How do I buy Bombay Oxygen Investments Limited () from Angel One?
- Direct investment: You can buy Bombay Oxygen Investments Limited () shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Bombay Oxygen Investments Limited () shares.
Today's live share price for Bombay Oxygen Investments SHARE PRICE [LIVE] is NSE: N/A, BSE: ₹ 10,900.00 with a current market capitalization of .
Bombay Oxygen Corporation (BOCL) was incorporated in 1960 to manufacture and market industrial gases. Shyam M Ruia is the chairman of the company. The company's manufacturing facilities are located in Nagpur, Tarapur, Pune, Nira, Khopoli, Kalwe and Mulund, all in Maharashtra. BOCL has a collaboration with General Electrodes and Equipments, Germany. The company has also entered into an agreement for procuring engineering services from Messer AGS Gmbh. In Mar.'95, it installed a capacity of 2.37 lac cu mtr for the manufacture of oxygen. The company manufactures various industrial gases such as oxygen, nitrogen, argon, compressed air, acetylene and medicinal oxygen. Its subsidiaries -- Savita Pharmaceuticals and Raptakos Brett & Company -- are engaged in the manufacture and distribution of pharmaceuticals. The company has designed and developed an indigenous cryogenic liquid oxygen pump for high-pressure gas-filling purposes. In 1996, the company has dis-invested in the shares of Raptakos Brett & Co. Therefore, Raptakos Brett & Co as also its subsidiaries, Raptakos Brett Test Laboratries and Sattva Pharmaceuticals ceased to be the company's subsidiaries. The company is also implementing new large tonnage Oxygen plant of 130 TPD at Kalwe, the same is expected to go on stream in 1999.Read more